| Literature DB >> 34040262 |
Lewis Au1,2, Annika Fendler1, Scott T C Shepherd1,2, Karolina Rzeniewicz1, Maddalena Cerrone3,4, Fiona Byrne1, Eleanor Carlyle2, Kim Edmonds2, Lyra Del Rosario2, John Shon5, Winston A Haynes5, Barry Ward1, Ben Shum1,2, William Gordon1, Camille L Gerard1,6, Wenyi Xie1, Nalinie Joharatnam-Hogan2, Kate Young2, Lisa Pickering2, Andrew J S Furness2, James Larkin2, Ruth Harvey7, George Kassiotis8, Sonia Gandhi9,10, Charles Swanton11, Charlotte Fribbens12,13, Katalin A Wilkinson3, Robert J Wilkinson3,4, David K Lau13, Susana Banerjee14, Naureen Starling13, Ian Chau13, Samra Turajlic15,16.
Abstract
Patients with cancer are currently prioritized in coronavirus disease 2019 (COVID-19) vaccination programs globally, which includes administration of mRNA vaccines. Cytokine release syndrome (CRS) has not been reported with mRNA vaccines and is an extremely rare immune-related adverse event of immune checkpoint inhibitors. We present a case of CRS that occurred 5 d after vaccination with BTN162b2 (tozinameran)-the Pfizer-BioNTech mRNA COVID-19 vaccine-in a patient with colorectal cancer on long-standing anti-PD-1 monotherapy. The CRS was evidenced by raised inflammatory markers, thrombocytopenia, elevated cytokine levels (IFN-γ/IL-2R/IL-18/IL-16/IL-10) and steroid responsiveness. The close temporal association of vaccination and diagnosis of CRS in this case suggests that CRS was a vaccine-related adverse event; with anti-PD1 blockade as a potential contributor. Overall, further prospective pharmacovigillence data are needed in patients with cancer, but the benefit-risk profile remains strongly in favor of COVID-19 vaccination in this population.Entities:
Year: 2021 PMID： 34040262 DOI： 10.1038/s41591-021-01387-6
Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440